Robeco Institutional Asset Management B.V. Sells 134,627 Shares of Biogen Inc. $BIIB

Robeco Institutional Asset Management B.V. reduced its position in shares of Biogen Inc. (NASDAQ:BIIB) by 17.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 656,465 shares of the biotechnology company’s stock after selling 134,627 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Biogen were worth $148,282,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Bell Investment Advisors Inc acquired a new stake in Biogen in the second quarter valued at about $27,000. Align Financial LLC increased its position in Biogen by 339.3% during the 3rd quarter. Align Financial LLC now owns 123 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 95 shares during the period. SHP Wealth Management acquired a new position in Biogen during the 4th quarter worth approximately $39,000. Ashurst Perkins Coie Trust Co increased its position in Biogen by 92.2% during the 3rd quarter. Ashurst Perkins Coie Trust Co now owns 173 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 83 shares during the period. Finally, Cassaday & Co Wealth Management LLC purchased a new position in shares of Biogen during the 1st quarter worth approximately $40,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Down 0.9%

BIIB stock opened at $240.98 on Thursday. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The company’s 50-day moving average price is $221.92 and its 200 day moving average price is $205.19. Biogen Inc. has a 52 week low of $138.00 and a 52 week high of $244.65. The company has a market cap of $35.60 billion, a P/E ratio of 42.65, a P/E/G ratio of 2.71 and a beta of 0.09.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company had revenue of $2.74 billion during the quarter, compared to analysts’ expectations of $2.46 billion. During the same period last year, the company posted $5.47 earnings per share. The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, research analysts expect that Biogen Inc. will post 12.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Zacks Research raised Biogen from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. Citigroup lifted their price target on Biogen from $200.00 to $215.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Guggenheim upped their price objective on Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. UBS Group increased their price objective on Biogen from $240.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, October 9th. Finally, Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and increased their price objective for the stock from $190.00 to $235.00 in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $240.86.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Positive kidney-disease data: Biogen highlighted 76-week EMPAVELI data showing sustained proteinuria reduction, stable kidney function and a consistent safety profile in C3G and primary IC-MPGN. Additional felzartamab and nephrology programs strengthened investor confidence in the company’s expanding renal franchise. Biogen nephrology data announcement
• Positive Sentiment: Higher analyst price target: Wells Fargo raised its BIIB target from $250 to $310 and maintained an “overweight” rating, signaling significant potential upside based on the company’s pipeline and growth prospects.
• Positive Sentiment: Earnings optimism: Zacks expects Biogen to beat consensus estimates in its upcoming third-quarter report, citing favorable earnings and revenue trends. The company is scheduled to report on October 28, making the release a near-term catalyst. Biogen earnings preview
• Positive Sentiment: Pipeline and strategic-growth expectations: Biogen is being featured among biotechnology companies with promising late-stage drug programs and upcoming regulatory or clinical milestones. The Apellis transaction is also expected to become increasingly accretive to adjusted earnings beginning in 2027. Zacks biotech pipeline commentary

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.